Cullinan Therapeutics, Inc. (CGEM) vs Pacira BioSciences, Inc. (PCRX)
A side-by-side comparison of Cullinan Therapeutics, Inc. and Pacira BioSciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CGEM
Cullinan Therapeutics, Inc.
$16.38HealthcareDelayed quote: Oct 6, 2026, 1:55 PM EDT
PCRX
Pacira BioSciences, Inc.
$24.70HealthcareDelayed quote: Oct 6, 2026, 1:50 PM EDT
Total return — CGEM vs PCRX
growth of $100 · dividends reinvested · last 6yCGEM -46.4% (-9.9%/yr)PCRX -58.6% (-13.7%/yr)CGEM compounded faster over this window
CGEM PCRX
CGEM vs PCRX: by the numbers
- •CGEM is the larger company ($1.01B vs $971M market cap).
- •PCRX is profitable (1.96% net margin) while CGEM runs a net loss (0.00%).
Metrics side by side
Valuation
| Metric | CGEM | PCRX |
|---|---|---|
| P/E ratio | N/A | 70.30 |
| P/S ratio | N/A | 1.30 |
| P/B ratio | 3.13 | 1.45 |
| EV / EBITDA | N/A | 11.37 |
| FCF yield | N/A | 18.48% |
Profitability
| Metric | CGEM | PCRX |
|---|---|---|
| Gross margin | 0.00% | 79.21% |
| Operating margin | 0.00% | 2.47% |
| Net margin | 0.00% | 1.96% |
| ROE | -63.62% | 2.18% |
| ROIC | -68.64% | 1.35% |
Growth (annualized)
| Metric | CGEM | PCRX |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 8.20% |
| EPS CAGR (5Y) | N/A | -45.77% |
| FCF CAGR (5Y) | N/A | 16.72% |
| Total return CAGR (5Y) | -7.48% | -12.27% |
Frequently asked
- Is CGEM or PCRX more profitable?
- PCRX runs the higher net margin — CGEM at 0.00% versus PCRX at 1.96%.
- How have CGEM and PCRX total returns compared?
- Over the past 5 years, CGEM delivered -7.48% and PCRX delivered -12.27% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Pacira BioSciences P/E ratioCullinan Therapeutics ROEPacira BioSciences ROECullinan Therapeutics operating marginPacira BioSciences operating marginCullinan Therapeutics revenue growthPacira BioSciences revenue growthCullinan Therapeutics free cash flowPacira BioSciences free cash flow
Cullinan Therapeutics & Pacira BioSciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.